InvestorLens

SRPT — SAREPTA THERAPEUTICS INC

Public company

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying SRPT?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 2 buying vs 0 selling last quarter
68
Macro Tailwind
Macro conditions are mixed for this sector
56
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their SRPT position last quarter, 2 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Howard Marks, Ray Dalio)
  • +5 tracked investors reported holding SRPT at their latest filing
  • +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About SAREPTA THERAPEUTICS INC (SRPT)

SAREPTA THERAPEUTICS INC (SRPT) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $216M. Across recent filings, tracked investors recorded 6 new positions, 8 increased, 5 reduced, and 4 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in SRPT

61
/100
Institutional Accumulation
Added / Increased14
Reduced5
Exited4
BearishBullish
Crowded Trade Score™

How many top investors track SRPT

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

SRPT Ownership Composition

How SAREPTA THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
87% of tracked value
Institutions
5
tracked investors
Total Reported
$67.5M
combined 13F value
Types3
  • Multi-Strategy / Quant86.5%
  • Value & Distressed9.4%
  • Macro4.1%
Multi-Strategy / Quant(3)
86.5%
Value & Distressed(1)
9.4%
Macro(1)
4.1%

Tracked investors currently reporting SRPT

2 tracked investors have since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    1.5M
    Value
    $27.7M
    % Portfolio
    0.00%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    1.2M
    Value
    $21.4M
    % Portfolio
    0.01%
  • Howard MarksJun 30, 2026
    Oaktree Capital Management
    Shares
    6.7M
    Value
    $6.3M
    % Portfolio
    0.09%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    510.9K
    Value
    $9.2M
    % Portfolio
    0.01%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    152.1K
    Value
    $2.7M
    % Portfolio
    0.01%

Previously held SRPT

These investors reported SRPT in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Paul Tudor JonesTudor Investment Corp68.7M$60.4MSep 30, 2025
George SorosSoros Fund Management230.9K$28.1MDec 31, 2024

Recent activity

Frequently asked questions

How many institutional investors hold SRPT?
5 tracked institutional investors disclosed a position in SRPT (SAREPTA THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of SRPT?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in SRPT, valued at $216M.
Did institutional ownership of SRPT increase or decrease?
Across recent 13F filings, tracked investors recorded 6 new positions, 8 increased, 5 reduced, and 4 fully exited SRPT.
Where does this SRPT ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.